The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tygacil     N-[(5aR,6aS,7S,9Z,10aS)-9- (amino-hydroxy...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tigecycline


High impact information on Tigecycline

  • The presence of tet(M) or tet(K) had no discernible effect on the tigecycline MICs for either MRSA or MSSA strains, which is consistent with the ability of the glycylcyclines to retain activity in the presence of both the ribosomal protection and efflux mechanisms of resistance to the tetracyclines [6].
  • Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections [7].
  • In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals [8].
  • Modeling data were consistent with the biochemical and biophysical data generated in this and other recent studies and suggested that tigecycline binds to bacterial ribosomes in a novel way that allows it to overcome tetracycline resistance due to ribosomal protection [9].
  • Biophysical analyses demonstrated that isolated ribosomes bind tigecycline, minocycline, and tetracycline with dissociation constant values of 10(-8), 10(-7), and >10(-6) M, respectively [9].

Chemical compound and disease context of Tigecycline


Biological context of Tigecycline

  • Trans-complementation with plasmid-borne ramA restored the original parental phenotype of decreased susceptibility to tigecycline [15].
  • Few human data are available regarding the adverse effects or drug interactions resulting from tigecycline therapy; however, preliminary data report that tigecycline can be safely used, is well tolerated and that the adverse effects experienced were typical of the tetracyclines (i.e. nausea, vomiting and headache) [16].
  • Time-kill kinetics demonstrated a >3 log(10) difference in viable growth when tigecycline was tested in fresh or Oxyrase-supplemented MHB compared to aged MHB [17].
  • Transposon mutagenesis of a clinical isolate of Morganella morganii, G1492 (tigecycline MIC of 4 microg/ml), yielded two insertion knockout mutants for which tigecycline MICs were 0.03 microg/ml [18].
  • Wild-type levels of decreased susceptibility to tigecycline were restored to the insertion mutants by complementation with a clone containing a PCR-derived fragment from the parental wild-type acrRAB efflux gene cluster [19].

Anatomical context of Tigecycline

  • Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs) [20].
  • Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose [21].
  • For the tigecycline bone penetration group, the bone concentrations of tigecycline in the infected tibia were significantly higher than the non-infected ones [22].
  • OBJECTIVES: The purpose of this study was to determine the tissue and corresponding serum concentration of tigecycline at selected time points in gall bladder, bile, colon, bone, synovial fluid (SF), lung and CSF in subjects undergoing surgical or medical procedures [21].
  • Metabolic studies in humans have revealed that tigecycline undergoes very limited metabolism and the primary route of elimination of unchanged drug is through the feces, with glucuronidation and renal elimination as secondary routes [23].

Associations of Tigecycline with other chemical compounds


Gene context of Tigecycline


Analytical, diagnostic and therapeutic context of Tigecycline


  1. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Livermore, D.M., Woodford, N. Trends Microbiol. (2006) [Pubmed]
  2. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. McAleese, F., Petersen, P., Ruzin, A., Dunman, P.M., Murphy, E., Projan, S.J., Bradford, P.A. Antimicrob. Agents Chemother. (2005) [Pubmed]
  3. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Pachón-Ibáñez, M.E., Jiménez-Mejías, M.E., Pichardo, C., Llanos, A.C., Pachón, J. Antimicrob. Agents Chemother. (2004) [Pubmed]
  4. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Morosini, M.I., García-Castillo, M., Coque, T.M., Valverde, A., Novais, A., Loza, E., Baquero, F., Cantón, R. Antimicrob. Agents Chemother. (2006) [Pubmed]
  5. Impact of Enterococcus faecalis on the Bactericidal Activities of Arbekacin, Daptomycin, Linezolid, and Tigecycline against Methicillin-Resistant Staphylococcus aureus in a Mixed-Pathogen Pharmacodynamic Model. Laplante, K.L., Rybak, M.J., Leuthner, K.D., Chin, J.N. Antimicrob. Agents Chemother. (2006) [Pubmed]
  6. Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Jones, C.H., Tuckman, M., Howe, A.Y., Orlowski, M., Mullen, S., Chan, K., Bradford, P.A. Antimicrob. Agents Chemother. (2006) [Pubmed]
  7. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Van Wart, S.A., Owen, J.S., Ludwig, E.A., Meagher, A.K., Korth-Bradley, J.M., Cirincione, B.B. Antimicrob. Agents Chemother. (2006) [Pubmed]
  8. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Denis, O., Deplano, A., Nonhoff, C., Hallin, M., De Ryck, R., Vanhoof, R., De Mendonça, R., Struelens, M.J. Antimicrob. Agents Chemother. (2006) [Pubmed]
  9. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Olson, M.W., Ruzin, A., Feyfant, E., Rush, T.S., O'Connell, J., Bradford, P.A. Antimicrob. Agents Chemother. (2006) [Pubmed]
  10. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model. Nannini, E.C., Pai, S.R., Singh, K.V., Murray, B.E. Antimicrob. Agents Chemother. (2003) [Pubmed]
  11. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Goldstein, E.J., Citron, D.M., Merriam, C.V., Warren, Y., Tyrrell, K. Antimicrob. Agents Chemother. (2000) [Pubmed]
  12. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Edelstein, P.H., Weiss, W.J., Edelstein, M.A. Antimicrob. Agents Chemother. (2003) [Pubmed]
  13. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Petersen, P.J., Bradford, P.A., Weiss, W.J., Murphy, T.M., Sum, P.E., Projan, S.J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  14. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Gales, A.C., Jones, R.N. Diagn. Microbiol. Infect. Dis. (2000) [Pubmed]
  15. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Ruzin, A., Visalli, M.A., Keeney, D., Bradford, P.A. Antimicrob. Agents Chemother. (2005) [Pubmed]
  16. The glycylcyclines: a comparative review with the tetracyclines. Zhanel, G.G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J.A., Hoban, D.J. Drugs (2004) [Pubmed]
  17. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Bradford, P.A., Petersen, P.J., Young, M., Jones, C.H., Tischler, M., O'Connell, J. Antimicrob. Agents Chemother. (2005) [Pubmed]
  18. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Ruzin, A., Keeney, D., Bradford, P.A. Antimicrob. Agents Chemother. (2005) [Pubmed]
  19. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Visalli, M.A., Murphy, E., Projan, S.J., Bradford, P.A. Antimicrob. Agents Chemother. (2003) [Pubmed]
  20. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). Ong, C.T., Babalola, C.P., Nightingale, C.H., Nicolau, D.P. J. Antimicrob. Chemother. (2005) [Pubmed]
  21. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. Rodvold, K.A., Gotfried, M.H., Cwik, M., Korth-Bradley, J.M., Dukart, G., Ellis-Grosse, E.J. J. Antimicrob. Chemother. (2006) [Pubmed]
  22. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. Yin, L.Y., Lazzarini, L., Li, F., Stevens, C.M., Calhoun, J.H. J. Antimicrob. Chemother. (2005) [Pubmed]
  23. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Meagher, A.K., Ambrose, P.G., Grasela, T.H., Ellis-Grosse, E.J. Diagn. Microbiol. Infect. Dis. (2005) [Pubmed]
  24. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Wallace, R.J., Brown-Elliott, B.A., Crist, C.J., Mann, L., Wilson, R.W. Antimicrob. Agents Chemother. (2002) [Pubmed]
  25. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Breedt, J., Teras, J., Gardovskis, J., Maritz, F.J., Vaasna, T., Ross, D.P., Gioud-Paquet, M., Dartois, N., Ellis-Grosse, E.J., Loh, E. Antimicrob. Agents Chemother. (2005) [Pubmed]
  26. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Hirata, T., Saito, A., Nishino, K., Tamura, N., Yamaguchi, A. Antimicrob. Agents Chemother. (2004) [Pubmed]
  27. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Patel, R., Rouse, M.S., Piper, K.E., Steckelberg, J.M. Diagn. Microbiol. Infect. Dis. (2000) [Pubmed]
  28. Tigecycline is modified by the flavin-dependent monooxygenase TetX. Moore, I.F., Hughes, D.W., Wright, G.D. Biochemistry (2005) [Pubmed]
  29. Tigecycline: a novel glycylcycline. Rubinstein, E., Vaughan, D. Drugs (2005) [Pubmed]
  30. Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates. McAleese, F., Murphy, E., Babinchak, T., Singh, G., Said-Salim, B., Kreiswirth, B., Dunman, P., O'Connell, J., Projan, S.J., Bradford, P.A. Antimicrob. Agents Chemother. (2005) [Pubmed]
WikiGenes - Universities